Summary & Overview
HCPCS J2910: Aurothioglucose Injection, Up to 50 mg
HCPCS Level II code J2910 designates injection of aurothioglucose up to 50 mg, an older injectable agent historically used for certain inflammatory conditions. Nationally, precise coding for injectable therapies matters for claims processing, clinical tracking, and historical utilization reporting. This code identifies a discrete drug administration event and supports appropriate billing and recordkeeping for outpatient injectable therapy.
Key payers in scope for this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical role of the drug formulation linked to the code, the typical sites where the service is delivered, and the operational considerations for billing an injectable medication in outpatient settings. The publication also summarizes benchmarks and payer policy considerations where available, highlights common modifier use, and points to related billing topics for injectable therapies.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific reimbursement rates. The focus remains national and clinical-operational: what the code represents, where it is used, and what readers should expect when encountering HCPCS Level II code J2910 in claims and clinical documentation.
Billing Code Overview
HCPCS Level II code J2910 describes the administration of aurothioglucose injection, up to 50 mg. The service represented is an injectable disease-modifying therapy delivered as a single-dose medication formulation. The typical site of service for this injection is outpatient clinic or physician office, though administration may also occur in ambulatory infusion centers depending on clinical workflow and payer rules.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with active rheumatoid arthritis or other inflammatory arthropathy for whom parenteral gold therapy (aurothioglucose) is being administered as part of disease-modifying therapy. The patient presents to an outpatient infusion or procedure area staffed by a rheumatology nurse and supervising rheumatologist. Pre-procedure evaluation includes vital signs, review of prior allergic reactions to gold compounds, recent laboratory testing (CBC, renal and liver function), and confirmation of indication. The medication J2910 (injection, aurothioglucose, up to 50 mg) is prepared by pharmacy or by the clinic under sterile technique. The nurse verifies the correct dose, documents lot number and expiration, and administers the injection intramuscularly per protocol. Post-injection monitoring for 15–30 minutes for hypersensitivity or local reaction is performed. Documentation includes indication, dose, route, site of injection, lot number, patient tolerance, and any immediate adverse events. Typical sites of service are outpatient hospital-based infusion centers, ambulatory surgical centers when coordinated with other procedures, and physician office-based injection clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to administer or coordinate J2910 is substantially greater than typically required (requires documentation). |